15,665 Bristol Myers Squibb Company $BMY Shares Sold by Castle Rock Wealth Management LLC

Posted by George Bondi on Oct 9th, 2026

Castle Rock Wealth Management LLC lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 32.7% during the third quarter, Holdings Channel.com reports. The firm owned 32,204 shares of the biopharmaceutical company’s stock after selling 15,665 shares during the period. Castle Rock Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $1,919,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BMY. BlackRock Inc. raised its holdings in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. State Street Corp grew its holdings in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Bristol Myers Squibb by 0.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Independent Franchise Partners LLP raised its stake in shares of Bristol Myers Squibb by 1.0% in the fourth quarter. Independent Franchise Partners LLP now owns 20,828,148 shares of the biopharmaceutical company’s stock worth $1,123,470,000 after acquiring an additional 204,797 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers reported that its ZENBEXUS (iberdomide) combination achieved superior progression-free survival versus standard of care in the Phase 3 EXCALIBER-RRMM trial for relapsed or refractory multiple myeloma. The results also showed high minimal residual disease-negative complete response rates and could support an application for accelerated FDA approval, strengthening BMY’s oncology pipeline. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
Positive Sentiment: J.P. Morgan reportedly assigned BMY a Buy rating, while recent commentary highlights the company’s oncology and hematology portfolio and its history of earnings surprises. These factors may support investor confidence in future growth and earnings. Bristol Myers Squibb Receives a Buy from J.P. Morgan

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Cantor Fitzgerald decreased their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. HSBC reaffirmed a “hold” rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Raymond James Financial began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Finally, Morgan Stanley reissued an “underweight” rating and issued a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $64.96.

Read Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 0.7%

BMY traded down $0.40 during trading on Friday, reaching $59.18. 9,252,673 shares of the company’s stock were exchanged, compared to its average volume of 12,002,556. The company’s fifty day moving average price is $64.27 and its 200-day moving average price is $60.28. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The firm has a market capitalization of $120.89 billion, a PE ratio of 13.04, a P/E/G ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.